Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23089517 | 0.92 | CYP2D6 (0.46) | OPRM1CYP3A4SIGMAR1CYP2D6TSHR | |
| SCHEMBL2604321 | 0.92 | OPRM1 (0.56) | OPRM1CYP3A4HSD17B10SIGMAR1TMEM97 | |
| SCHEMBL17714545 | 0.87 | OPRM1 (0.51) | OPRM1CYP3A4HSD17B10SIGMAR1TMEM97 | |
| SCHEMBL9177367 | 0.85 | OPRM1 (0.54) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL22050088 | 0.79 | OPRM1 (0.60) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL2276510 | 0.75 | MEN1 (0.48) | HSD17B10 | |
| SCHEMBL23285144 | 0.75 | OPRL1 (0.44) | CYP3A4HSD17B10SIGMAR1TMEM97OPRL1 | |
| SCHEMBL2275141 | 0.75 | OPRM1 (0.57) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL28123157 | 0.74 | CYP3A4 (0.45) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL23285145 | 0.72 | OPRL1 (0.39) | OPRM1CYP3A4HSD17B10SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | OPRM1 3553/4885CYP3A4 4307/4885HSD17B10 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.